Time Course of Glatiramer Acetate Efficacy in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in the Glatiramer Acetate Low-Frequency Administration (GALA) Study

被引：0
|
作者：
Kolodny, S. [1 ]
Davis, M. D. [2 ]
Ashtamker, N. [3 ]
Steinerman, J. R. [2 ]
Knappertz, V. [2 ,4 ]
机构：
[1] Teva Pharmaceut Ind, Cleveland, OH USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Teva Pharmaceut Ind, Netanya, Israel
[4] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-47
引用
收藏
页码：333 / 334
页数：2
相关论文
共 50 条
  • [1] Predictors of Disability in Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate Low-frequency Administration (GALA) Study
    Alexander, Jessica
    Daudt, Donald R.
    Davis, Mat D.
    Ashtamker, Natalia
    Kolodny, Scott
    [J]. NEUROLOGY, 2017, 88
  • [2] Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients
    Rio, Jordi
    Rovira, Alex
    Tintore, Mar
    Sastre-Garriga, Jaurne
    Castillo, Joaquin
    Auger, Cristina
    Nos, Carlos
    Comabella, Manuel
    Tur, Carmen
    Vidal, Angela
    Montalban, Xavier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (12) : 1602 - 1608
  • [3] Glatiramer acetate: Promise in relapsing-remitting multiple sclerosis?
    不详
    [J]. Drugs & Therapy Perspectives, 1998, 11 (10) : 1 - 5
  • [4] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [5] Spotlight on Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
    Dene Simpson
    Stuart Noble
    Caroline Perry
    [J]. BioDrugs, 2003, 17 : 207 - 210
  • [6] Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis
    Simpson, D
    Noble, S
    Perry, C
    [J]. BIODRUGS, 2003, 17 (03) : 207 - 210
  • [7] Efficacy and safety of a 3 times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Boyko, A. N.
    Selmaj, K. W.
    Ashtamker, N.
    Davis, M. D.
    Kolodny, S.
    Zivadinov, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 711 - 711
  • [8] Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
    Taskapilioglu, Ozlem
    Turan, Asli Bahar
    Albas, Murat
    Turan, Omer Faruk
    [J]. TURKISH JOURNAL OF NEUROLOGY, 2012, 18 (01) : 17 - 20
  • [9] Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Kolodny, S.
    Davis, M. D.
    Ashtamker, N.
    Steinerman, J. R.
    Zivadinov, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 119 - 120
  • [10] Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Di Pietrantonj, Carlo
    Rovaris, Marco
    Rigon, Giulio
    Frau, Serena
    Berardo, Francesco
    Gandini, Anna
    Longobardi, Anna
    Weinstock-Guttman, Bianca
    Vaona, Alberto
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (09): : 1016 - 1020
12345